3 ms·
> Results from the six-month Japanese clinical trial — in which 137 patients were randomized to receive either Radicava or placebo Giving placebo to ALS patien
by ekianjo 10y ago
> Results from the six-month Japanese clinical trial — in which 137 patients were randomized to receive either Radicava or placebo
Giving placebo to ALS patients? How is that allowed ? They should be able to tell already what is the course of a typical ALS patient without using such methods. For cancer drugs there are no placebo used since there is extensive survival data available to prove whether or not a drug actually makes any difference.
- satai 10y agoYou have to get rid of placebo effect. It can be pretty strong in an (supposedly) advanced drug tests. >For cancer drugs there are no placebo used since there is extensive survival data available to prove whether or not a drug actually makes any difference. Source, please?
- ekianjo 10y agoAre you kidding me ? Are you assuming I don't know what I am commenting about ? http://www.cancer.net/navigating-cancer-care/how-cancer-treated/clinical-trials/placebos-cancer-clinical-trials http://www.cancer.net/navigating-cancer-care/how-cancer-trea... "In past years, it was generally not necessary or possible to use placebos in cancer clinical trials."
- carbocation 10y agoPlacebo isn't used because there are treatments that are effective (even if the effect is small). Therefore, the placebo comparison is (for many cases) unethical. The appropriate comparison is to the standard therapy, not to no therapy at all. If there is no therapy that is known to be effective for a particular illness, then placebo control remains appropriate.
- ekianjo 10y ago> If there is no therapy that is known to be effective for a particular illness, then placebo control remains appropriate. For cancer there's almost always some kind of combination that gives some results (even if not great). So your statement proves what I said. > Use of placebo controls may be justified in these situations: > To prove effectiveness of a new treatment for diseases with high placebo response rates > In conditions that alternately become worse or better, have spontaneous remissions (the disappearance of the signs and symptoms of cancer, but not necessarily the entire disease), or have an uncertain and unpredictable course > When existing therapies are minimally effective or have serious side effects > In the absence of any effective therapy